Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivo

1 Nov 2024

Abstract excerpt

Safe, effective, and low-cost oral antiviral therapies are needed to treat those at high risk for developing severe COVID-19. To that end, we performed a high-throughput screen to identify non-peptidic, non-covalent inhibitors of the SARS-CoV-2 main protease (Mpro), an essential enzyme in viral replication. NZ-804 was developed from a screening hit through iterative rounds of structure-guided medicinal chemistry....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Influenza Virus Research Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39504242
DOI: 10.1016/j.celrep.2024.114929

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivoPMID 39504242Read ↗

A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variantsSemantic proximity Read ↗

Novel inhibitors against COVID-19 main protease suppressed viral infectionSemantic proximity Read ↗

Inhibition mechanism and antiviral activity of an α-ketoamide based SARS-CoV-2 main protease inhibitorSemantic proximity Read ↗

Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative StudySemantic proximity Read ↗

Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19Semantic proximity Read ↗

Inhibition mechanism and antiviral activity of an α-ketoamide based SARS-CoV-2 main protease inhibitorSemantic proximity Read ↗

Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19Semantic proximity Read ↗

Next-generation inhibitors of SARS-CoV-2 Mpro overcome the deficiencies of Paxlovid.Semantic proximity Read ↗

Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19Semantic proximity Read ↗

Development of small molecule non-covalent coronavirus 3CL protease inhibitors from DNA-encoded chemical library screeningSemantic proximity Read ↗

Oral administration of S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and accelerates recovery from clinical aspects of COVID-19Semantic proximity Read ↗

Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.